Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
Search
:::

林裕誠 (Yu-Cheng Lin)

林裕誠(Yu-Cheng Lin)圖 Return Appointment First Appointment

[Profile]

  • Education
    • Bachelor of Medicine, College of Medicine; National Taiwan University ,
    • Doctor of Medicine, Graduate Institute of Clinical Medicine; National Taiwan University,
  • Career and Experience
    Current Positions：
    • - Now, Attending physician, Department of Pediatrics, Taipei Veterans General Hospital,
    • - Now, Chief, Pediatric Gastroenterology, Taipei Veterans General Hospital,
    • - Now, Board Member, Taiwan Society of Pediatric Gastroenterology, Hepatology, and Nutrition,
    • - Now, Board Member, Chinese Taipei Society for the Study of Obesity,
    • - Now, Director, Taiwan Children Liver Foundation,
    • - Now, Scientific Committee Member, Asia Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition,
    • - Now, Committee Member, Research Committee, Taiwan Pediatric Association,
    • - Now, Committee Member, Pediatric Gastroenterology Committee, Taiwan Pediatric Association,
    Experiences：
    • - , Attending Physician, Department of Pediatrics, Far Eastern Memorial Hospital,
    • - , Director, Department of Medical Affairs, Far Eastern Memorial Hospital,
    • - , Director, Pediatric Emergency Department, Far Eastern Memorial Hospital,
    • - , Director, Core Laboratory, Far Eastern Memorial Hospital,
    • - , Reviewer, Department of Life Sciences, National Science and Technology Council,
  • Medical Expertise
    1. Pediatric and Adolescent Obesity, Fatty Liver
    2. Growth Delay in Infants, Nutritional Counseling for Infants and Young Children
    3. Pediatric and Adolescent Gastrointestinal Diseases: Vomiting, Diarrhea, Abdominal Pain, Constipation, GI Bleeding, etc.
    4. Prevention and Treatment of Pediatric and Adolescent Liver and Gallbladder Diseases
    5. Abdominal Ultrasound, Gastroduodenoscopy, Colonoscopy, Fibroscan
  • License
    Pediatrician Pediatric Gastroenterologist Obesity Specialist Adolescent Medicine Specialist Gastrointestinal Endoscopy Specialist

[Publications]

  1. Lin YC, Liao FM, Chao HC, Chen AC, Jeng YM, Lin CC, Tiao MM, Yang YJ, Yeung CY, Chen HL, Ni YH. Consensus statement on metabolic dysfunction-associated steatotic liver disease in children and adolescents from the joint TASL-TSPGHAN expert committee. JGH Open. [Accepted for publication].

  2. Lin YC, Wu CC, Li YE, Chen CL, Lin CR, Ni YH. Full-length 16S rRNA sequencing reveals gut microbiome signatures predictive of MASLD in children with obesity. BMC Microbiol. 2025;25(1):146.

  3. Lin YC, Liu PC, Chou FF, Hou IC, Chou CC, Chen CW, Hu SH, Chen SP, Lo HJ, Huang FF. Beliefs underlying weight control behaviors among adolescents and emerging adults living with obesity: an elicitation qualitative study. BMC Public Health. 2024;24(1):3292.

  4. Chen CL, Huang FF, Lin HF, Wu CC, Ni YH, Lin YC. Tat-beclin-1 peptide ameliorates metabolic dysfunction-associated steatotic liver disease by enhancing hepatic autophagy. Int J Mol Sci. 2024;25(22):12372.

  5. Chang PS, Chang PF, Lin YC. Usefulness of the triglyceride glucose index to predict nonalcoholic fatty liver disease in children with obesity. J Pediatr. 2023;255:260–261.

  6. Liu PC, Lin YC, Gau BS, Tung HH, Hu SH, Chen CW. Association between lifestyle-related, psychosocial factors and obesity among female adolescents in Taiwan. J Pediatr Nurs. 2023;68:e58–e68.

  7. Lin YC, Chang PF, Ni YH. Updated upper limits of normal serum alanine aminotransferase levels for screening metabolic dysfunction-associated fatty liver disease in obese children. J Formos Med Assoc. 2022;121:2548–2555.

  8. Chen CL, Lin YC. Autophagy dysregulation in metabolic associated fatty liver disease: a new therapeutic target. Int J Mol Sci. 2022;23(17):10055.

  9. Lin YC, Lin HF, Wu CC, Chen CL, Ni YH. Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity. J Gastroenterol. 2022;57:913–925.

  10. Lin YC, Chang PF, Liu K, Chang MH, Ni YH. Predictors for incidence and remission of nonalcoholic fatty liver disease in obese children and adolescents. J Formos Med Assoc. 2022;121:36–42.

  11. Lin YC, Wu CC, Ni YH. New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease. Front Pediatr. 2020;8:603654.

  12. Huang MJ, Lin YC, Liu K, Chang PF, Huang CS. Effects of variation status and enzyme activity for UDP-glucuronosyltransferase 1A1 gene on neonatal hyperbilirubinemia. Pediatr Neonatol. 2020;61(5):506–512.

  13. Liu HH, Lin YC, Chung CS, Liu K, Chang YH, Yang CH, Chen Y, Ni YH, Chang PF. Integrated counts of carbohydrate-active protein domains as metabolic readouts to distinguish probiotic biology and human fecal metagenomes. Sci Rep. 2019;9(1):16836.

  14. Lin YC, Chang PF, Chang MH, Ni YH. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children. Liver Int. 2018;38(7):1300–1307.

  15. Chitturi S, Wong VW, Chan WK, et al. (incl. Lin YC). The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33(1):86–98.

  16. Wong VW, Chan WK, Chitturi S, et al. (incl. Lin YC). The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85.

  17. Lin YC, Ni YH. Reply to: “Title: The IRGM rs10065172 variant increases the risk for steatosis but not for liver damage progression in Italian obese children.” J Hepatol. 2017;67(3):655–656.

  18. Lin YC, Chang PF, Lin HF, Liu K, Chang MH, Ni YH. Variants in the autophagy related gene IRGM confer susceptibility to nonalcoholic fatty liver disease by modulating lipophagy. J Hepatol. 2016;65(6):1209–1216.

  19. Chang PF, Lin YC, Liu K, Yeh SJ, Ni YH. Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease. Int J Obes. 2015;39(8):1236–1240.

  20. Lin YC, Chang PF, Chang MH, Ni YH. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr. 2014;99(4):869–874.

  21. Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr. 2013;97(2):326–331.

  22. Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for nonalcoholic fatty liver disease in obese Taiwanese children. J Pediatr. 2011;158(5):740–744.

  23. Lin YC, Chang PF, Yeh SJ, Liu K, Chen HC. Risk factors associated with liver steatosis in obese children and adolescents. Pediatr Neonatol. 2010;51(3):149–154.

  24. Lin YC, Chang PF, Hu FC, Chang MH, Ni YH. Variants in the UGT1A1 gene and the risk of pediatric non-alcoholic fatty liver disease. Pediatrics. 2009;124(6):e1221–e1227

 

 

[研究計畫  Research Projects – Yu-Cheng Lin]

<國科會-個人型 / NSTC Research Project Grant>

探討CD36以自噬機制調控代謝相關脂肪肝病之角色

Deciphering the role of CD36, a fatty acid transporter, in metabolic associated fatty liver disease via autophagy mechanism

<國科會-整合型 / NSTC Research Project Grant>

結合雲端技術APP、腸道菌叢檢測及多體學等先進科技探討台灣肥胖青少年非酒精性脂肪肝精準醫療的策略－開發多基因風險評分模式來預測肥胖兒童青少年對於減重介入的成效

Development of Polygenic Risk Score to Predict the Efficacy of Weight Loss Intervention in Children and Adolescents with Obesity

<114年臺北榮總暨台大醫院兩院合作研究 / 2025 TVGH–NTUH Joint Project>

揭示腸道BlautiaWexlerae的治療潛力：緩解代謝功能障礙相關脂肪肝病的機制探討

Exploring the Therapeutic Potential of Blautia wexlerae in the Gut Microbiota: Mechanistic Insights into Alleviating Metabolic Dysfunction-Associated Steatotic Liver Disease

<114年臺北榮總院內計畫 / 2025 TVGH Research Project Grant >

多巴胺第三型受體(DRD3)在代謝性脂肪肝病中的角色

Role of Dopamine Receptor D3 (DRD3) in Metabolic-Associated Fatty Liver Disease

<114年兒童肝膽疾病防治基金會計畫 / 2025 Taiwan Children Liver Foundation Grant>

Serum Metabolomics Signature for Obese Children with Metabolic Dysfunction-Associated Steatotic Liver Disease
回到最上